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The urokinase-type plasminogen activator receptor (uPAR) is a cell surface receptor which has a multifunctional task in the
process of tumorigenesis including cell proliferation, adhesion, migration, and invasion. Many of the biological functions of uPAR
necessitate interactions with other proteins. We have shown previously that uPAR interacts with HAX1 protein (HS-1-associated
protein X-1). In the current study, to gain insight into the possible role of HAX1 overexpression in regulation of uPAR signal
transduction pathway, several function assays were used. We found that, upon stimulation of uPAR, HAX1 colocalizes with uPAR
suggesting a physiological role for HAX1 in the regulation of uPAR signal transduction. HAX1 overexpression augments cell
proliferation and migration in uPAR-stimulated cells. Moreover, HAX1 over-expression augmented uPAR-induced cell adhesion
to vitronectin as well as cellular invasion. Our results suggest that HAX1 over-expression may underlay a novel mechanism to
regulate uPAR-induced functions in cancer cells.
1.Introduction
The urokinase-type plasminogen activator (uPA) receptor
(uPAR) has been implicated in cell proliferation, migration,
adhesion, invasion, and signal transduction apart from its
role in extracellular matrix (ECM) and basement membrane
proteolysis [1]. The uPAR protein consists of three domains
(DI,DII,andDIII)[2].uPARDIistheligand-bindingsitefor
uPA [3], whilst uPAR DII and DIII host the binding sites for
other proteins such as integrins and vitronectin (Vn) [4, 5].
TheactiveuPAconsistsofcatalyticproteasedomainanduPA
amino terminal fragment (uPA-ATF) [6]. uPA-ATF contains
thekringledomainandthegrowthfactor-likedomain(GFD)
[6]. GFD contains the binding sequence for the receptor [6].
uPA system has been shown to be involved in cell prolif-
eration. Transfection of relatively low uPAR expressing MS-1
human pleural mesothelial cells with uPAR cDNA increased
proliferation and migration in vitro and tumor formation
in vivo [7]. Moreover, it has been shown that suppression
of uPAR inhibits proliferation and migration of pancreatic
adenocarcinoma cells via regulation of extracellular signal-
regulated kinases (ERK)/p38 signaling [8]. Cells that were
treated with uPA, uPA-ATF, or uPAR-devoid of domain 1
were activated, leading to their enhanced migration [9, 10].
uPA can inﬂuence cell migration by directly cleaving ECM
proteins such as ﬁbronectin [11], or by activating pro-
transforming growth factor-β (pro-TGF-β)[ 12], and pro-
hepatocyte growth factor (pro-HGF) [13]. On the contrary,
the intratumoral or systemic delivery of uPA-ATF gene
induced signiﬁcant inhibition of angiogenesis-associated
tumor growth, invasion, and metastasis of tumor cells in
vivo[14, 15]. Furthermore, endogenous uPA-ATF expression
repressed invasion and metastasis of lung cancer cells [16].
In addition, uPA-ATF has also shown to restrain the invasion
of breast carcinoma [17]. Recently, soluble uPAR has been
found to be involved in chondrosarcoma cell mobilization
[18]. We have recently identiﬁed HAX1 (HS-1-associated
protein X-1) as a novel partner of uPAR [19]. Initially, to2 Journal of Oncology
identify a functional signiﬁcance of the interaction between
HAX1 and uPAR, we demonstrated the colocalization of
u P A Ra n dH A X 1i nd i ﬀerent cell lines upon stimulation of
cells with diﬀerent stimulants to uPAR signal transduction
pathway. These stimulants included epidermal growth factor
(EGF), uPA, and uPA-ATF. Subsequently, we showed for
the ﬁrst time that HAX1 overexpression could augment cell
proliferation, migration, adhesion, and invasion induced by
uPAR.
2.MaterialandMethods
2.1. Cell Lines, Transfection, and Reagents. The human em-
bryonic kidney HEK293 cells stably transfected with uPAR
were kindly provided by Dr. Ying Wei (University of
California, San Francisco, CA, USA). The human breast
cancer MDA-MB-231 and the human osteosarcoma Saos-
2 cell lines were obtained from American Tissue Culture
Collection (ATCC). Cells were maintained in Dulbecco’s
modiﬁed Eagle’s medium supplemented with 10% fetal calf
serum (FCS) and 1% antibiotics. The pGEM-3Zf(+)\HAX1
vector was kindly provided by Dr. Maria Olsson (G¨ oteborg
University, Sahlgrenska University Hospital, Gothenburg,
Sweden). Cells were transfected with recombinant or control
vector in addition to GFP plasmid to control transfection
eﬃciency. All transfections were carried out using GeneJuice
(no. 70967, Novagen, Germany), according to manufac-
turer’s instructions. Goat anti-human uPAR antibody was
purchased from R&D Systems (no. AF807, USA). Rabbit
anti-human HAX1 antibody (no. sc-28268) was purchased
fromSantaCruzBiotechnologyInc.Therecombinantanalog
EGF was obtained from Sigma-Aldrich (no. E-4269, USA).
The recombinant human uPA was purchased from R&D
systems (no. 1310-SE, USA). The recombinant human uPA-
ATF was obtained from American Diagnostics (no. 146,
USA).
2.2. Confocal Microscopy. Transfected cells with pGEM-
3Zf(+)\HAX1 were seeded onto sterilized glass cover slips.
For the stimulation experiments, cells were serum-starved
overnight, treated with 100ng/mL EGF, uPA, or uPA-
ATF for 20min, washed with PBS, and ﬁxed with 0.5%
formaldehyde/PBS/0.1% sodium azide for 1h. Afterwards,
cells were washed and incubated in 70% ethanol for 1h at
4◦C. Fixed cells were washed, blocked with 1% BSA, and
then incubated with polyclonal rabbit anti-human HAX1
and goat anti-human uPAR and primary antibodies in 1%
BSA, followed by anti-rabbit FITC-conjugated and anti-goat
Rhodamine phalloidin-conjugated secondary antibodies in
1% BSA. After washing, cover slips were mounted and
cells analysed using confocal Olympus IX71 Laser Scanning
Microscope to determine the extent of colocalization.
2.3. MTT Proliferation Assay. Proliferation assay was per-
formed as previously described [20]. Brieﬂy, 1 × 105
cells/well were cultured in 96-well plates and incubated
at 37◦Ci n5 %C O 2 incubator for 24h. At the endpoint,
cells were incubated with MTT 0.5mg/mL for further 4h.
Resulting formazan crystals were dissolved with 100μL
DMSO (dimethyl sulfoxide). Absorbance was measured at
570nm using a 96-well plate reader.
2.4. Migration Assay. Eﬀect of HAX1 on cell migration
was studied using wound healing procedure as reported by
Rodriguez et al. [21]. Cells were seeded into culture dishes
and incubated for 24h at 37◦C. The cells were transfected
with either pGEM-3Zf(+)\HAX1 or pGEM-3Zf(+) empty
plasmidandincubatedat37◦Cin5%CO 2 tocreateconﬂuent
monolayer. A scratch was created manually by scrapping the
cell monolayer with yellow pipette tip. After washing, 5mL
of culture media with 2% FCS was added to culture media.
The ﬁrst image was taken by using marks on the culture dish
as a reference point. Cells were stimulated with EGF, uPA,
or uPA-ATF 100ng/mL media or left without stimulation as
a control and incubated in the CO2 incubator for 18h at
37◦C, and then the second image was acquired. These images
wereanalysedquantitativelybymeasuringthedistanceofthe
wounded region migrated by cells in pixels.
2.5. Cell Adhesion Assay. The assay was performed as
previously described with minor modiﬁcations [22]. Brieﬂy,
96-well dishes were precoated with 2μg/mL Vn or heat-
denaturedBSA(Sigma-Aldrich)overnightat4◦C.Wellswere
rinsed with PBS and incubated with 2% heat-denatured BSA
to block any uncoated areas. Cells (1.5 × 105/well) were
seededinthecoatedwellsandincubatedfor2hat37◦C.After
washing the attached cells were ﬁxed with methanol/acetone
and stained with 0.1% crystal violet. The stain was eluted
using acetic acid/methanol/water and absorbance measured
at 595nm with a 96-well plate reader.
2.6. Cell Invasion Assay. Cell invasion was measured using
24-well Transwell system with polycarbonate membranes of
8mm pore size. The membranes were coated with 20μg/mL
collagen IV at 4◦C overnight. Transfected cells (2 × 105/well)
were seeded onto the upper-side chambers in 0.2mL of
serum-freeDMEMmediumand0.6mLofthesamemedium
containing 1% FCS was added to the lower chamber. The
cells were allowed to adhere for 1h. Then chemotaxis was
induced by the addition of 100ng/mL EGF, uPA, or uPA-
ATFtothelowerchamber.Media containing 10% FCSor1%
FCS were used as positive and negative controls, respectively.
After 18h, cells that invaded through the membrane to
the lower surface were Giemsa stained and counted in ﬁve
diﬀerent ﬁelds under the light microscope.
2.7. Statistical Analysis. Data is expressed as the mean ±
S.D. and where appropriate, the Student’s t-test. Results were
considered statistically signiﬁcant when P<0.05.
3. Results
3.1. HAX1 Colocalized with uPAR upon Stimulation of Cells
with EGF, uPA, and uPA-ATF. uPA binding to uPAR trig-
gers both proteolysis of ECM and signal transduction.
Immunoﬂuorescence studies were performed to investigateJournal of Oncology 3
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Figure 1: HAX1 colocalizes with uPAR upon stimulation of cells with uPA and uPA-ATF. (A) HEK293/uPAR and (B) MDA-MB-231 cells
were transfected with pGEM-3Zf(+)\HAX1, kept as negative control (a) or serum-starved overnight (b) and then treated with 100ng/mL
of either EGF (c), uPA, (d) or uPA-ATF (e) for 20min. Cells were ﬁxed and then immunostained with antibodies against uPAR (red) and
HAX1 (green), and colocalization appeared as yellow colour. These cells were analysed using confocal laser scanning microscope and 60x oil
immersion lens (ﬁnal magniﬁcation 600x).
the cellular distribution of HAX1 and its localization with
uPAR following stimulation of cells with EGF, uPA, or uPA-
ATF. HEK293/uPAR and MDA-MB-231 cells transfected
with HAX1 were employed for this experiment (Figure 1). In
actively proliferating cells cultured in growth media, HAX1
was located in the cytoplasm. However, uPAR was primarily
localized on the cell membrane and in the cytoplasm. In
cells cultured in serum-starved media, HAX1 colocalization
with uPAR was diminished (Figure 1). A subset of HAX1 was
found to colocalize with uPAR upon stimulation of cells with
EGF, uPA, or uPA-ATF (Figure 1), suggesting a physiological
role for HAX1 in the regulation of uPAR signal transduction.
Based on this observation along with our ﬁnding that uPAR
interacts with HAX1, we decided to investigate the role of
HAX1 as regulator of uPAR signal transduction pathway in
cells stimulated with EGF, uPA, and uPA-ATF using diﬀerent
function assays.
3.2. HAX1 Is Involved in uPAR-Induced Cell Proliferation. To
demonstrate the physiological impact of HAX1 overexpres-
sion on uPAR-induced cell proliferation, MTT proliferation4 Journal of Oncology
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Figure 2:HAX1overexpressionaugmentsHEK293/uPARandMDA-MB-231cellproliferationinuPAR-stimulatedcells.(a)HEK293/uPAR.
(b) MDA-MB-231 cells were transfected with pGEM-3Zf(+) (light bars) or pGEM-3Zf(+)\HAX1 (dark bars). Cells were exposed to 10%
FCS alone or with 100ng/mL of EGF, uPA, or uPA-ATF. Cell proliferation was measured using MTT assay. Data is expressed as mean ± S.E
of optic density (OD) readings; ∗∗∗ represents P<0.001 using unpaired Student’s t-test.
assay was performed using HEK293/uPAR and MDA-MB-
231 cells transfected with pGEM-3Zf(+)\HAX1 or pGEM-
3Zf(+)emptyplasmid.Cellswerestimulatedwith100ng/mL
of EGF, uPA, or uPA-ATF, while other cells were left
without stimulation as a control group. Proliferation of
HEK293/uPAR cells transfected with pGEM-3Zf(+)\HAX1
compared to cells transfected with vector plasmid was signif-
icantly increased (P<0.001) in control group (10% FCS-
treated cells) (Figure 2). Proliferation of cells transfected
with pGEM-3Zf(+)\HAX1 and stimulated with EGF, uPA,
or uPA-ATF led to profound increase in cell proliferation
(P<0.001) when compared to pGEM-3Zf(+)-transfected
cells.
3.3. Overexpression of HAX1 Increases uPAR-Induced Cell
Migration. PreviousreportsshowedthatuPARpromotescell
migration [23, 24]. To demonstrate the physiological impact
of HAX1 overexpression on uPAR-induced cell migration,
wound healing assays were performed using HEK293/uPAR,
HCT116, and MDA-MB-231 cells transfected with HAX1.
As shown in Figures 3(a)–3(c), migration of transfected
HEK293/uPAR cells with pGEM-3Zf(+)\HAX1 was on the
whole greater than cells transfected with pGEM-3Zf(+)
empty plasmid. In unstimulated cells, the transfection and
overexpression of HAX1 caused signiﬁcant (P<0.05)
increase of cell migration. After stimulation with EGF and
uPA, the increase of cell migration was signiﬁcant (P<
0.01) in cells transfected with HAX1 compared to cells
transfected with empty plasmid. Similarly, stimulation of
HAX1-transfected cells with uPA-ATF caused signiﬁcant
increase (P<0.05) in cell migration. The results obtained
from MDA-MB-231 were almost identical to those of
HEK293/uPAR cell line. Stimulation of MDA-MB-231 cells
with uPA caused signiﬁcant increase (P<0.01) of cell
migration in cells transfected with HAX1 compared to cells
transfected with empty plasmid.
3.4. HAX1 Augments uPAR-Induced Cell Adhesion. Adhesion
of cells to extracellular matrix protein Vn is an important
event in cancer progression and metastasis. Using cell adhe-
sion assay, we investigated the possibility that cell adhesion
to Vn may be enhanced in response to HAX1 overexpres-
sion upon stimulation with EGF, uPA, and uPA-ATF. As
presented in Figure 3(d), adhesion to Vn of HEK293/uPAR
cells transfected with pGEM-3Zf(+)\HAX1 compared to
cells transfected with vector plasmid was nonsigniﬁcant
(P>0.05) in control group. However, upon treatment
with EGF, the adhesion of cells transfected with pGEM-
3Zf(+)\HAX1 was increased (P<0.05) in comparison
to those transfected with pGEM-3Zf(+) empty plasmids.
Adhesion of cells transfected with pGEM-3Zf(+)\HAX1 and
treated with uPA was signiﬁcantly increased (P<0.001)
when compared to pGEM-3Zf(+)-transfected cells. Cells
treated with uPA-ATF signiﬁcantly increased (P<0.01)
adhesion of cells transfected with HAX1. These results
reveal that HAX1 overexpression augments uPAR-induced
cell adhesion to extracellular matrix Vn.
3.5. Overexpression of HAX1 Induces uPAR-Dependant Cell
Invasion. To determine whether HAX1 overexpression in-
duces uPAR-induced invasion in MDA-MB-231 and Saos-2
cells,wecarriedoutinvitrocellinvasionassays.EGFanduPA
increased cellular invasiveness of MDA-MB-231 and Saos-
2 cells transfected with pGEM-3Zf(+) (Figure 4). However,
the catalytically inactive uPA-ATF caused suppression of
cell invasiveness (Figure 4). Compared to control pGEM-
3Zf(+)-transfected cells, these cells transfected with pGEM-
3Zf(+)\HAX1 had signiﬁcantly increased their invasive
capacity (Figure 4). This was reﬂected in the signiﬁcant
increase (P<0.001) in the number of invasive cells
expressing HAX1 upon stimulation with EGF. However,
stimulation with uPA and its catalytically inactive uPA-ATF
caused a signiﬁcant increase (P<0.01) of cells invasiveness.Journal of Oncology 5
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Figure 3: HAX1 overexpression increases cell migration and adhesion in uPAR-stimulated cells. (a) HEK293/uPAR, (b) HCT116, and (c)
MDA-MB-231 cells were transfected with pGEM-3Zf(+) (light bars) or pGEM-3Zf(+)\HAX1 (dark bars) and examined using wound
healing assay. A monolayer of conﬂuent cells was scratched with a 200μL pipette tip and the closure of the scratch was observed in the
presence of either 10% FCS, 1% FCS, or 100ng/mL of EGF, uPA, or ATF. Photographs were taken immediately and after 18h of creating the
scratch. Cell migration was assessed by measuring the distance migrated by cells in pixels in these 18h. (d) HAX1 augments HEK293/uPAR
cell adhesion. 1.5 × 105 cells/well transfected with pGEM-3Zf(+) (light bars) or pGEM-3Zf(+)\HAX1 (dark bars) were seeded in precoated
96-well plate with 2μg/mL Vn or heat-denatured BSA, treated with 100ng/mL of EGF, uPA, or uPA-ATF, and incubated for 2h at 37◦C.
After washing, the attached cells were ﬁxed with methanol/acetone and stained with 0.1% crystal violet. The stain was eluted using acetic
acid/methanol/water and absorbance measured at O.D595. Bars are mean ± S.E using unpaired Student’s t-test (n.sP>0.05; ∗P < 0.05; ∗∗P <
0.01; ∗∗∗P < 0.001).
4. Discussion
Expression of uPAR has been shown to aﬀect several cellular
processes including proliferation, migration, adhesion, as
well as invasion, and its expression has been associated
with malignancy of cancers [25]. Since uPAR lacks a trans-
membrane domain and only attached with membrane by
an extracellular glycosyl phosphatidylinositol (GPI) anchor,
it uses the interaction with other partner proteins to
activate signal transduction [26] .S e v e r a ls t u d i e sh a v es h o w n
that transmembrane receptors and cytoplasmic signaling
proteinsformacomplexwithorcontributeinuPAR-induced
signalling[25].Theidentiﬁcationofnewinteractingproteins
which may bind to uPAR will allow us to better understand
its complex and important role in cancer progression.
Recently, we identiﬁed HAX1 as a partner protein of uPAR
using yeast two-hybrid, GST-pull down, coimmunoprecip-
itation assays and confocal microscopy [19]. HAX1 has
been found to be overexpressed in breast cancer, lung
cancer,andmelanoma[27,28],althoughtheexactmolecular
mechanism by which overexpression of HAX1 may provide
an oncogenic role needs to be evaluated. Our preliminary
data indicates that both HAX1 and uPAR are simultaneously
increased in aggressive (e.g., MDA-MB-231 and PC3) but
notinnonaggressive(e.g.,MCF-7)cancercells.Weproposed
that one of these may indeed be via its ampliﬁcation of
uPAR signal transduction. To gain insight into the uPAR-
induced functions regulated by HAX1, we stimulated uPAR
w i t hu P Aa n du P A - A T Fa sw e l la sE G F .T h eE G Fr e c e p t o r
(EGFR) selectively has been found to cooperate with uPAR
to mediate mitogenesis [29]. Our results showed profound
colocalization between uPAR and HAX1 in cytoplasm of6 Journal of Oncology
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Figure 4: HAX1 induces cell invasion in uPAR-stimulated tumor cells. (a) MDA-MB-231 and (b) Saos-2 cells were transfected with pGEM-
3Zf(+) (light bars) or pGEM-3Zf(+)\HAX1 (dark bars) and placed in Transwell inserts and were exposed to either 10% FCS, 1% FCS, or
100ng/mL of EGF, uPA, or ATF. Cell migration was assessed by counting stained (c) MDA-MB-231 and (d) Saos-2 cells on the membrane
after 18h. Data is expressed as mean ± S.E. of O.D readings (n = 5) using unpaired Student’s t-test (n.sP > 0.05; ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P
< 0.001).
bothserum-starvedandstimulatedcells.Thiswasinteresting
asHAX1 appearsto be predominantly localized to cytoplasm
compartments [30], while uPAR is located in the cell
membrane and cytoplasm in normal and neoplastic tissues
[31, 32].
HAX1 has been also found to interact with several
proteins implicated in the regulation of cell migration such
as cortactin (an F-actin-associated protein) [33], the hairpin
element present in the 3 UTR of the transcript of vimentin
(a cytoskeletal protein) [34]. The presence of a quaternaryJournal of Oncology 7
complex consisting of HAX1, Gα13, Rac, and cortactin
indicates the role of HAX1 in the regulation of cytoskeletal
components involved in cell movement. Since the expres-
sion of HAX1 potentiates Gα13-mediated cell movement,
silencing of endogenous HAX1 with HAX1-speciﬁc siRNAs
signiﬁcantly reduces Gα13-mediated cell migration. These
ﬁndings, together with the observation that HAX1 is overex-
pressed in metastatic tumors and tumor cell lines, suggest a
role for HAX1/Gα13 association in tumor metastasis [35]. In
another study, HAX1 has been shown to bind to the integrin
αvβ6, an integrin linked to the aggressive invasive behavior
of carcinoma cell and poor clinical prognosis in cancer
patients[36].ReductionofHAX1levelsbysiRNAsuppressed
αvβ6-dependent migration and invasion through clathrin-
mediated endocytosis of αvβ6. Following the silencing of
HAX1 expression, the impaired migration was independent
of apoptotic events but operated through αvβ6 endocytosis
[36]. In a recent study, HAX1 has been found to interact
with several other proteins as a novel integrin-linked kinase
(ILK) conﬁrming the contribution of HAX1 in the integrin
signaling pathway [37]. The role of HAX1 in inhibition
of apoptosis and regulation of cell migration, the two
critical processes in carcinogenesis and tumor metastasis,
was supported by the fact that HAX1 is highly expressed in
diﬀerent types of human cancers [27, 36]. In the current
study, we showed that HAX1 overexpression augments
uPAR-induced cell proliferation, migration, adhesion, and
invasion. These processes are crucial in tumor progression
and metastasis. uPA binding to uPAR focuses plasmin-
mediated ECM degradation to the leading edge of migrating
cells and thereby facilitates cellular penetration of tissue
boundaries [38]. uPAR interactions with Vn and integrins
modify the strength of cellular adhesion [39, 40]. Laminin-5,
amarkerofinvadingcancercellsinsomehumancarcinomas,
is coexpressed with uPAR in budding cancer cells in colon
adenocarcinomas [41]. In addition, there have been shown
integrin-mediated cell adhesion to laminin-5 potentiates cell
invasion and matrix metalloproteinase (MMP) production
gastric carcinoma [42] .S o ,i ti sl i k e l yt h a ta c t i v a t i o no fu P A R
byHAX1coordinateswithintegrinstopromotecelladhesion
to extracellular matrix proteins including vitronectin and
laminin-5. Moreover, uPA has been found to initiate ECM
proteolysis which is involved in many processes in which
cell migration occurs, including tumor cell invasion [43]
and monocyte inﬁltration [38]. Furthermore, uPA has been
shown to stimulate adhesion and chemotactic movement of
myeloid cells [44], to induce cell migration in human ECs
[45], independently of its proteolytic activity.
In conclusion, our results showed that HAX1 overex-
pression augments cell proliferation and migration in uPAR-
stimulatedcells.Moreover,HAX1overexpressionaugmented
uPAR-induced cell adhesion to vitronectin as well as cellular
invasion. These results suggest a novel mechanism for
regulation of uPAR-induced cellular functions which may
extend our understanding of the precise role of uPAR in
cancer molecular biology. Further work to identify the exact
downstream signal transduction pathway by which HAX1
modulates these functions is currently under investigation in
our laboratories.
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ATCC: American tissue culture collection
DMSO: Dimethyl sulfoxide
ECM: Extracellular matrix
EGF: Epidermal growth factor
EGFR: EGF receptor
ERK: Extracellular signal-regulated kinases
FCS: Fetal calf serum
GFD: Growth factor-like domain
GPI: Glycosyl phosphatidylinositol
HAX1: HS-1 associated protein X-1
ILK: Integrin-linked kinase
MMP: Matrix metalloproteinase
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pro-TGF-β: Protransforming growth factor-β
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